Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. reports developments as a global animal health company serving veterinarians, livestock producers and pet owners. Its updates center on medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for companion animals and livestock, organized commercially through U.S. and International segments.
Recurring news includes quarterly results and guidance, dividend declarations, investor conference presentations, pipeline and product-regulatory updates, and portfolio activity tied to animal health innovation. Company materials also describe R&D work across areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity, as well as approved long-acting osteoarthritis pain products Lenivia and Portela.
Summary not available.
Summary not available.
Zoetis Inc. (NYSE:ZTS) will participate in the Credit Suisse 2020 Virtual Healthcare Conference on November 10, 2020. Glenn David, Executive Vice President and CFO, will represent the company, presenting at 11:00 a.m. ET. Investors can access a live audio webcast of the presentation via Zoetis' investor relations site. A replay will also be available post-event. Zoetis is a leading animal health company with over 65 years of experience, generating $6.3 billion in revenue in 2019 and serving clients in over 100 countries.
Zoetis Inc (NYSE:ZTS) has announced a fourth-quarter dividend of $0.20 per share, set to be paid on December 1, 2020. The dividend will benefit stockholders of record as of October 21, 2020. With a strong market position in animal health, Zoetis generated $6.3 billion in revenue in 2019, underscoring its operational strength across 100 countries. This dividend declaration reflects the company's commitment to returning value to shareholders while maintaining a solid financial framework.
Zoetis Inc (NYSE:ZTS) is set to hold a webcast and conference call on November 5, 2020, at 8:30 a.m. ET. CEO Kristin Peck and CFO Glenn David will discuss Q3 2020 financial results and answer questions from analysts. Investors can access the live presentation on Zoetis' investor website, with a replay available later on the same day. Zoetis continues to be a leading company in animal health, generating $6.3 billion in revenue in 2019 and serving customers across more than 100 countries.
On July 7, 2020, Trianni and Zoetis announced a collaboration to develop transgenic monoclonal antibody platforms aimed at discovering new veterinary treatments. This partnership is expected to leverage Trianni's advanced technology, which focuses on generating fully-human monoclonal antibodies, thus enhancing Zoetis' product development initiatives. The companies believe this collaboration will accelerate the creation of innovative therapeutics for animal health. No financial details regarding the collaboration have been disclosed.